Overview

The goal of the Accelerating Medicines Partnership® (AMP®) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment. (Read the program description by NIH here.) Collaborations with 10 companies and three NIH Institutes have been established across five major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid Arthritis (RA)/Lupus, Parkinson's disease and Schizophrenia.

Partners

Private-Sector Partners:

  • AbbVie* 
  • Biogen*
  • Bristol-Myers Squibb Company*
  • Eli Lilly and Company*
  • GlaxoSmithKline*
  • Johnson & Johnson*
  • Merck & Co., Inc.*
  • Novartis Institutes for BioMedical Research*
  • Pfizer Inc*
  • Pharmaceutical Research and Manufacturers of America*
  • Sanofi*
  • Takeda Pharmaceuticals International, Inc.*
  • UCB*

*Provided financial or in-kind support for this program.

Media
Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation

FNIH Contact

Accelerating Medicines Partnership® Program - Alzheimer's Disease

Accelerating Medicines Partnership® Program - Common Metabolic Diseases

Accelerating Medicines Partnership® Program Bespoke Gene Therapy

Accelerating Medicines Partnership® Program - RA/Lupus Project
 

Accelerating Medicines Partnership® Program – Type 2 Diabetes Project

 

ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.